Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 886 results for "sanofi"

Sanofi's combination diabetes drug hits goal in late-stage trial

LixiLan consists of a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma , and Sanofi's Lantus. Economic Times, 1 hour ago

445 images for sanofi

Pharmafile, 1 day ago
I4U, 1 day ago
DailyNews724.com, 1 day ago
Yahoo! News Australia, 2 days ago
The Malaysian Times, 4 days ago
Reuters, 2 days ago
The Cyprus Weekly, 4 days ago
MSN News US, 4 days ago
The Cyprus Weekly, 4 days ago
Money Control, 1 week ago
TeleTrader.com

Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 3 percent Tuesday after the company announced a new global collaboration with Sanofi (NYSE: SNY) to "discover, develop and commercialize new antibody cancer ...
 Benzinga.com13 hours ago Regeneron, Sanofi Announce Immuno-Oncology Collaboration  Benzinga.com22 hours ago EMA committee recommends marketing approval forPraluen to treat hypercholesterolemia  PharmaBiz1 day ago Regeneron, Sanofi Launch $2B+ Immuno-Onc...  Genetic Engineering News8 hours ago
[x]  
CTV News

French dengue vaccine backed by data analysis

(Washington, United States) - A dengue vaccine candidate by French drugmaker Sanofi protects more than three quarters of participants, an analysis found Monday. The experimental drug allowed 80.8 per cent of children aged nine and older to avoid ...
 CTV News19 hours ago Data analyses back Sanofi dengue vaccine: study  Yahoo! India1 day ago AFP - US-France-health-vaccine-research  Namibia Press Agency1 day ago Sanofi says new data analyses support its dengue vaccine  Yahoo! India1 day ago
[x]  
Pharma Letter

Sanofi links with Regeneron in $2.17 billion cancer drug push

French drugmaker Sanofi said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals in the hot area of cancer immunotherapy. Sanofi will make an upfront payment of $640 million to ...
 Economic Times21 hours ago Sanofi links with Regeneron in $2.2 bln cancer drug push  Reuters1 day ago Sanofi pledges $2.17 billion in new deal with Regeneron28-07-2015  Pharma Letter22 hours ago Sanofi links with Regeneron in US$2.2 billion cancer drug push  Channel NewsAsia1 day ago
[x]  
Money Control

Sanofi and Regeneron Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal

July 27, 2015 By Mark Terry , BioSpace.com Breaking News Staff Tarrytown, N.Y.-based Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. ( REGN ) announced today it had inked a global collaboration agreement with Paris-based Sanofi ( ...
 BioSpace17 hours ago AstraZeneca PLC Divests Yet Another Drug, This Time to Sanofi for $300 Million  BioSpace1 day ago Sanofi (SNY), Regeneron (REGN)'s 's $15,000-a-Year Heart Drug May Trigger New Cost Concerns 7/27/2015  ClinicSpace1 day ago Sanofi (SNY) and Regeneron (REGN) Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal 7/28/2015  ClinicSpace16 hours ago
[x]  
Motley Fool

Sanofi SA And Regeneron Pharmaceuticals Extend Partnership In Cancer Treatments

Sanofi SA (ADR) ( NYSE:SNY ) and Regeneron Pharmaceuticals Inc. ( NASDAQ:REGN ) have further extended their collaboration and would now be working together on cancer therapies, designed to stimulate the immune system of patients to fight cancer ...
 Bidness Etc20 hours ago Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval  Motley Fool1 day ago

Sanofi India announces change in CFO

This page uses frames, but your browser doesn't
 Capital Market19 hours ago Sanofi India announces change in directorate  Business Standard19 hours ago Board of Sanofi India approves sale of land  Business Standard1 week ago
[x]  

Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

B ig pharmas Pfizer (NYSE: PFE ) and Merck (NYSE: MRK ) both beat Q2 estimates and raised guidance Tuesday, while Merck and French counterpart Sanofi (NYSE: SNY ) entered into separate deals to develop immunotherapy drugs for cancer. Pfizer's ...
 Investor's Business Daily13 hours ago
EuroInvestor

Sanofi Pasteur's vaccine candidate protects pre-adolescents to adults against dengue

Based on the clinical profile in nine years of age and older, the dengue vaccine candidate has the potential to significantly reduce disease burden in endemic countries Sanofi Pasteur's new data analysis published in the New England Journal of ...
 Financial Express22 hours ago Sanofi Pasteur's dengue vaccine candidate safely protects pre-adolescents  European Pharmaceutical Review14 hours ago Sanofi : New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue  4 Traders1 day ago New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue  Individual.com1 day ago
[x]  
TheStreet.com

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

Reddit Email Print Reprint NEW YORK ( TheStreet ) -- It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news. The answer to almost every Sanofi question about drug research and development appears to ...
 TheStreet.com16 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sanofi
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less